Vaccine countdown update: 10 Nov - positive results from some, cash flow concerns with others
A metal processor covered here would appear to justify a much higher rating, while cash flow concerns continue to cast a shadow over a once popular litigation funder. Read on here for more on these and other stories.
The news that Pfizer and Germany’s BioNTech have made progress with a Covid-19 vaccine saw stock markets soar, although not all stocks rose, with some beneficiaries of the pandemic, notably small UK biotech stocks, falling sharply, as many clearly think their glory days will soon be coming to an end. This seems somewhat premature to us, with plenty of work ahead before the vaccine becomes available to everyone and many biotech companies still likely to be short term beneficiaries of the current uncertainty and ongoing need for mass testing. Notwithstanding, with a first vaccine on the horizon, we thought it…